<code id='74AEC1A081'></code><style id='74AEC1A081'></style>
    • <acronym id='74AEC1A081'></acronym>
      <center id='74AEC1A081'><center id='74AEC1A081'><tfoot id='74AEC1A081'></tfoot></center><abbr id='74AEC1A081'><dir id='74AEC1A081'><tfoot id='74AEC1A081'></tfoot><noframes id='74AEC1A081'>

    • <optgroup id='74AEC1A081'><strike id='74AEC1A081'><sup id='74AEC1A081'></sup></strike><code id='74AEC1A081'></code></optgroup>
        1. <b id='74AEC1A081'><label id='74AEC1A081'><select id='74AEC1A081'><dt id='74AEC1A081'><span id='74AEC1A081'></span></dt></select></label></b><u id='74AEC1A081'></u>
          <i id='74AEC1A081'><strike id='74AEC1A081'><tt id='74AEC1A081'><pre id='74AEC1A081'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:explore    - browse:5687
          Illustration of two DNA strands made of banknotes. -- health coverage from STAT
          Adobe

          The staff of the Institute for Clinical and Economic Review, or ICER, are known as the nerds of the drug industry: bespectacled killjoys who emerge a few times a year to scold drugmakers for pricing their latest cancer or MS advance far beyond reason.

          But last year, they sat down and concluded a forthcoming treatment was worth up to $3.9 million — more than any medicine in history, more than a 45-year supply of Humira, the autoimmune drug often held up as an emblem of America’s runaway drug spending. 

          advertisement

          It was a testament to the power of a new class of gene therapies to deliver something pharma so rarely does: Genuine cures. The treatment, approved last week as Lenmeldy, may allow some babies born with an ultra-rare neurodegenerative disease called metachromatic leukodystrophy, or MLD, to grow up and live essentially normal lives.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus